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Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and
Antibiotic Synergy
John W. Lamppa,a* Karl E. Griswolda,b
Thayer School of Engineeringa and Molecular and Cellular Biology Program,b Dartmouth, Hanover, New Hampshire, USA
More than 2 decades of study support the hypothesis that alginate lyases are promising therapeutic candidates for treating mu-
coid Pseudomonas aeruginosa infections. In particular, the enzymes’ ability to degrade alginate, a key component of mucoid bio-
film matrix, has been the presumed mechanism by which they disrupt biofilms and enhance antibiotic efficacy. The systematic
studies reported here show that, in an in vitro model, alginate lyase dispersion of P. aeruginosa biofilms and enzyme synergy
with tobramycin are completely decoupled from catalytic activity. In fact, equivalent antibiofilm effects can be achieved with
bovine serum albumin or simple amino acids. These results provide new insights into potential mechanisms of alginate lyase
therapeutic activity, and they should motivate a careful reexamination of the fundamental assumptions underlying interest in
enzymatic biofilm dispersion.
Premature mortality among cystic fibrosis (CF) patients is typ-ically associated with chronic airway infection by the oppor-
tunistic pathogen Pseudomonas aeruginosa (1). Upon coloniza-
tion of the airway, P. aeruginosa causes a range of clinical
complications, including stimulation of a hyperinflammatory re-
sponse, obstruction of the pulmonary tract, and progressive loss
of lung function (1–3). The bacterium’s persistence within the CF
lung is thought to result in large part from a biofilm mode of
growth (2, 4), which can subvert both the host immune response
and antibacterial therapies (5). In contrast to environmental
niches, in the CF lung, P. aeruginosa generally transitions to a
mucoid phenotype characterized by overproduction of the ex-
opolysaccharide alginate (6). This copolymer of (1,4)-linked
-D-mannuronic acid and-L-guluronic acid alters biofilm archi-
tecture and function (7) and thereby compounds P. aeruginosa’s
persistence in the chronically inflamed airway (5). Indeed, alg-
inate is one of themost extensively studied P. aeruginosa virulence
factors (8).
Given alginate’s contribution to mucoid biofilm structure, its
function in bacterial virulence, and its role in the persistent nature
of lung infections, it has long been considered an attractive target
for interventional therapies (6). In particular, biocatalytic degra-
dation of mucoid P. aeruginosa biofilms using alginate lyase en-
zymes (EC 4.2.2.3) has been the subject of more than 20 years of
research. Alginate lyase treatment has been shown to reduce vis-
cosity in cultures of clinical isolates and in CF sputum (9, 10); it
strips biofilms from abiotic surfaces (11, 12), it enhances phago-
cytosis and killing of P. aeruginosa by human immune cells (13–
15), and it improves the efficacy of various antipseudomonal an-
tibiotics (14, 16–19). In aggregate, these reports make a rather
convincing case for the use of inhaled alginate lyases for treating
chronic P. aeruginosa infections of the CF lung, although no clin-
ical trials have been conducted to date.
In an effort to further bolster the rationale for therapeutic alg-
inate lyases, we set out to conduct systematic studies analyzing the
solution phase kinetics, biofilm-disrupting potential, and antibi-
otic synergy of two promising enzyme candidates. Sphingomonas
sp. A1 alginate lyase (A1-III) has been shown previously to exhibit
high levels of activity toward bacterial alginate (20) and has also
been subjected to molecular engineering with an eye toward ther-
apeutic applications (12, 21). P. aeruginosa alginate lyase (AlgL) is
produced by the CF-associated pathogen itself, and its confirmed
role in bacterial alginate biosynthesis (22, 23) suggests the enzyme
is an obvious choice for developing alginate-degrading CF bio-
therapies. On a superficial level, our results are entirely consistent
with the encouraging outcomes of prior alginate lyase studies. Our
systematic approach, however, has for the first time revealed that
enzyme-mediated biofilm disruption and antibiotic synergy are
decoupled from catalytic activity. The results described here sug-
gest the need to carefully reexamine the veracity of fundamental
assumptions motivating interest in therapeutic alginate lyases.
MATERIALS AND METHODS
Bacterial strains. The mucoid P. aeruginosa clinical isolate FRD1 and its
nonmucoid derivative, SMC406, were obtained from the G. O’Toole lab-
oratory (Geisel School of Medicine at Dartmouth, Hanover, NH).
SMC406 varies from FRD1 only in the deletion of the algT gene, which
effectively eliminates alginate biosynthesis (24). The Escherichia coli ex-
pression strain SHuffle T7 Express {fhuA2 lacZ::T7 gene1 [lon] ompT
ahpC gal att::pNEB3-r1-cDsbC (Specr lacIq) trxB sulA11 R(mcr-73::
miniTn10-Tets)2 [dcm] R(zgb-210::Tn10 –Tets) endA1 gor (mcrC-
mrr)114::IS10}was purchased fromNewEnglandBioLabs (Ipswich,MA).
Cloning of the A1-III and AlgL alginate lyases.Thealginate lyase gene
algLwas amplified from the P. aeruginosaPAO1 genome using a 5= primer
with an ATG start codon, homology to base pairs 82 to 96 on the native
gene, and a 3= primer with either a TGA stop codon or a C-terminal
hexahistidine tag followedby aTGA stop codon. The amplifiedAlgL genes
were ligated into the pET28b expression vector and transformed into
electrocompetent SHuffle T7 Express. Individual clones were sequence
verified. Additionally, pET28b constructs containing either Sphingomo-
nas sp. alginate lyase A1-III or a C-terminal hexahistidine-tagged variant
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(A1-III–His) (12) were transformed into SHuffle T7 Express, and individ-
ual clones were sequence verified.
The catalytically inactivated double point mutant of A1-III–His (A1-
DM-His) was constructed by targeting two of the active-site residues in-
volved in the enzyme’s -elimination mechanism (25). Mutation H188A
consisted of switching the histidine 188 GTG codon to a CGC codon,
while mutation Y242F replaced the tyrosine 242 GTA codon with a GAA
codon. The mutated gene was then ligated into the pET28b expression
vector and transformed into SHuffle T7 Express, and individual clones
were sequence verified.
Expression and purification of alginate lyases.Expression hosts were
grown overnight in 8 ml of LB supplemented with 30 g/ml kanamycin
(LB-KAN30) at 30°C. The overnight cultures were then subcultured 1:100
into 500ml of fresh LB-KAN30 and grown tomid-log phase at 30°C, after
which the cells were equilibrated at 25°C for 30min and then inducedwith
0.5 mM IPTG (isopropyl--D-thiogalactopyranoside) for 21 h. Following
induction, the cell cultureswere centrifuged at 6,000 g at 4°C for 10min,
and the total cell pellet for each construct was resuspended in 5 ml of
buffer A (20mMNaH2PO4, pH 6.5). The resuspended pellets were trans-
ferred to 10-ml Pyrex beakers, equilibrated on ice for 20 min, and dis-
rupted by sonicationwith 24 cycles of 10 s on and 10 s off (Fisher 550 Sonic
Dismembrator).Whole-cell lysatewas centrifuged at 17,000 g at 4°C for
20 min, and the soluble fraction was filtered through a 0.22-m poly-
ethersulfone (PES) membrane.
Filtered soluble cell extract containing AlgL was loaded onto a 30-ml
hydroxyapatite column (Calbiochem, La Jolla, CA) equilibrated with buf-
fer A. Buffer A continued to run for 10 ml at 2 ml/min before changing to
a step gradient of 30% buffer A and 70% buffer B (500mMNaH2PO4, pH
6.5) for 60ml, followed by 100%buffer B for an additional 65ml. At 100%
buffer B, a single peak, containing AlgL and other proteins, was eluted.
This peak was dialyzed against 50 mM KH2PO4, 150 mM NaCl, pH 7, at
4°C and concentrated using a 10,000-molecular-weight cutoff (MWCO)
centrifugal filter. Concentrated sample (300 l) was then loaded onto a
120-ml Superdex75 size exclusion chromatography (SEC) (GE Health-
care Life Sciences, Piscataway, NJ) column equilibrated with 50 mM
KH2PO4, 150 mM NaCl, pH 7. Flow was maintained at 0.6 ml/min, and
purified AlgL was eluted as a single peak at 60 ml. Samples from the SEC
were concentrated using a 3,000-MWCO centrifugal filter and stored at
4°C. Enzyme purity was assessed by SDS-PAGE, and the final protein
concentrations weremeasured byA280 (NanoDrop 1000; Thermo Scientific,
Waltham, MA) using a molar absorptivity of 67,050 cm1 M1, estimated
with the VectorNTI software package (Invitrogen, Carlsbad, CA).
The same hydroxyapatite column and buffers were used to purify A1-
III enzyme from corresponding soluble cell extract. The column was
washed with buffer A for 20ml at 2ml/min, then increased to 5% B for 30
ml, increased again to 12% B for 50 ml, and finally 100% B for another 80
ml. An unresolved peak at 100 ml containing A1-III was collected and
dialyzed against 50mMKH2PO4, 150mMNaCl, pH 7 at 4°C before being
concentrated with a 10,000-MWCO centrifugal filter. Two hundred mi-
croliters of the concentrated sample was then loaded onto the same Su-
perdex75 SEC column, and purified A1-III was eluted at 60 ml under the
same conditions described above. Samples did not require further con-
centration after SEC and were stored at 4°C. Enzyme purity was assessed
by SDS-PAGE, and the protein concentration wasmeasured byA280 (mo-
lar absorptivity 63,350 cm1 M1).
In addition to the above-mentioned purification protocol, single-step
immobilizedmetal ion affinity chromatography (IMAC) purification was
also used as an alternative method for isolating the His-tagged variants.
Briefly, 4 to 5 ml of filtered soluble cell extract was gently mixed with a
0.4-ml bed volume of nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qia-
gen, Valencia, CA), which had been equilibrated with native lysis buffer
(50 mMNaH2PO4, 300 mMNaCl, and 10 mM imidazole, pH 8.0). Bind-
ing occurred at 4°C for 1 h, with gentle rocking, after which the column
was drained and washed with 10 bed volumes of wash buffer (50 mM
NaH2PO4, 300mMNaCl, and 20mM imidazole, pH 8.0). Purified A1-III
was eluted in a native elution buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 8.0), dialyzed into storage buffer (20 mM
NaH2PO4, pH 6.5), and kept at 4°C. Once again, enzyme purity was as-
sessed by SDS-PAGE, and concentrations were determined by A280.
Enzyme kinetic analysis with soluble substrates. Enzyme-mediated
cleavage of the alginate carbohydrate backbone through beta elimination
results in formation of a C-4–C-5 carbon-carbon 	 bond at the new
nonreducing termini, causing a strong absorbance peak at 235 nm. Rep-
licate kinetic analysis was conducted bymonitoring product formation at
235 nm in UV-transparent 96-well plates (Costar Fisher number 3635).
Using amultichannel pipette, 190-l aliquots ofmedium-viscosity brown
seaweed alginate (BSWA) (Sigma number A2033) weremixed thoroughly
with 10l of enzyme residing in each well of the plate’s upper row. BSWA
dilutions were prepared in a reaction buffer (150 mM NaCl, 50 mM
NaH2PO4, pH 7.0) and ranged from 0.01% to 0.1% (wt/vol). Upon com-
pletion of mixing, the plate was transferred to a UV-visible plate reader
(SpectraMax 190; Molecular Devices, Sunnyvale, CA), and the formation
of product was tracked every 15 s over the course of 10 min. Initial slopes
from absorbance-versus-time plots were determined for each substrate
concentration, and nonlinear regression of the initial reaction rates versus
substrate concentration was used to determine apparent Vmax and Km
values for each enzyme. Kinetics with bacterial alginate substrate, purified
from P. aeruginosa FRD1 as described previously (26), followed the same
procedure (bacterial alginate follows the same cleavage mechanism as
BSWA).
Biofilm cell viability assays. P. aeruginosa strains FRD1 and SMC406
were grown on LB agar plates at 37°C. Single colonies were selected and
used to inoculate 3-ml cultures of tryptic soy broth (TSB). The cultures
were placed on an orbital shaker for 21 h at 37°C before being diluted
1:1,000 in fresh TSB. Upon dilution, the cultures were aliquoted into
96-well minimum biofilm eradication concentration (MBEC) plates (In-
novotech, Edmonton, AB, Canada) at a volume of 75 l per well. The
corresponding peg lid was then placed on top of the plate, and the sides of
the plate were sealed with strips of Breathe-Easy membrane (Diversified
Biotech, Dedham, MA), which eliminated evaporation but still allowed
gas permeability. The plates were incubated statically at 37°C for 20 h
before the peg lids were removed, rinsed in sterile deionized water for 10
s, and placed into black, clear-bottom, 96-well treatment plates (Corning,
Lowell, MA). The treatment plates contained 125 l of activity buffer (50
mMpotassium phosphate, 150mMNaCl, pH 7) only (untreated) or with
one of the following agents: 100 or 500 g/ml tobramycin (MP Biomedi-
cals, Solon, OH), 1,000 g/ml protein (A1-III–His, A1-DM-His, A53C-
His-PEG [polyethylene glycol], AlgL-His, or bovine serum albumin
[BSA]), the constituent amino acids of A1-III–His at the same molar
concentrations contained in 1,000 g/ml of intact enzyme, the arginine
constituent of A1-III–His at the same molar concentration contained in
1,000 g/ml of the intact enzyme, or arginine at the same molar concen-
tration as the sum total of all amino acids in 1,000 g/ml A1-III–His.
Additionally, 100 or 500g/ml of tobramycin was combined with each of
the protein and amino acid treatments to assess synergistic effects. The
treatment plates were sealed with strips of Breathe-Easy membrane and
statically incubated at 37°C for 12 h.
After treatment, the peg lids were removed from the treatment plates,
rinsed in sterile deionized water for 10 s, and placed into black, clear-
bottom, 96-well plates containing 125 l per well of alamarBlue (Invitro-
gen, Carlsbad, CA) to measure biofilm cell viability. Concurrently, ala-
marBlue was added to the treatment plates to measure the viability of any
detached cells. All alamarBlue plates were sealed with Breathe-Easymem-
branes and statically incubated for 12 h at 37°C. Membranes and peg lids
were then removed, and reduction of the alamarBlue resazurin com-
pound was measured by fluorescence at an excitation wavelength of 540
nm (550-nm cutoff) and an emissionwavelength of 585 nm. Additionally,
alamarBlue background signal was measured in the presence of all treat-
ments without cells and subtracted from the cell viability signal.
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SEM. Polystyrene peg lids were prefixed in 0.1 M PIPES [piperazine-
N,N=-bis(2-ethanesulfonic acid)], pH 7, containing 50 mM L-lysine,
0.075% ruthenium red, and 2.5% glutaraldehyde for 30 min at room
temperature. The peg lids were then fixed in 0.1 M PIPES, pH 7, contain-
ing 0.075% ruthenium red and 2.5% glutaraldehyde for 3 h at room tem-
perature before being rinsedwith 0.1MPIPES, pH 7, for 20min (the rinse
was repeated three times). Dehydration of the peg lids was performed in
30%, 50%, 70%, and 95% ethanol for 5 min each, with 2 final changes in
100% ethanol for 5 min each. The peg lids were then air dried in a desic-
cator for 72 h. Upon completion of air drying, individual pegs were
snapped off from the lids with tweezers and mounted on scanning elec-
tron microscopy (SEM) stubs with a layer of melted apiezon wax. The
mounted pegs were then sputter coated with gold and palladium and
viewed by SEM (XL30 ESEM FEG; FEI, Hillsboro, OR).
Statistical analysis. Statistical significancewas assessed using one-way
analysis of variance (ANOVA) and post hoc Tukey’s multiple-comparison
tests. Significance was determined at an  value of 0.05.
RESULTS
Selection, cloning, and production of alginate lyases. We se-
lected two enzyme candidates for comparative analysis. Sphin-
gomonas sp. A1-III has been reported to exhibit particularly high
levels of activity toward bacterial alginate (20) and has been the
subject of extensive study and preclinical development (9, 12, 21).
P. aeruginosa AlgL has naturally evolved to degrade bacterial alg-
inate, and the enzyme was shown previously to facilitate detach-
ment of P. aeruginosa from biofilms (27). The algL gene was am-
plified from P. aeruginosa PAO1 genomic DNA, cloned into the
pET28b expression vector, and transformed into electrocompe-
tent E. coli SHuffle T7 Express. A gene encoding a variant of AlgL
bearing a C-terminal hexahistidine tag (AlgL-His) was con-
structed in a similar manner. Shake flask cultures of the two ex-
pression strains were induced overnight, and the proteins were
purified from whole-cell lysates via hydroxyapatite and then SEC.
The yields were 0.39 mg/liter for native AlgL and 2.3 mg/liter for
AlgL-His, with both proteins exhibiting 
90% purity (Fig. 1A).
The synthesis and cloning of genes encoding the native A1-III
enzyme and its C-terminal His-tagged variant have been de-
scribed previously (12). Expression and purification of A1-III and
A1-III–His followed the same procedures described for AlgL
above. The final yields for the two proteins were 9.3mg per liter of
bacterial culture and 15 mg per liter of culture, respectively, and
again, both proteins were
90% pure following SEC (Fig. 1B).
In addition to the two-step hydroxyapatite and SEC purifica-
tion described above, the His-tagged variants AlgL-His and A1-
III–His were purified by one-step IMAC nickel chromatography.
IMAC purification resulted in 7.6 mg AlgL-His per liter of bacte-
rial culture and 13mgA1-III–His per liter of culture. The purity of
the proteins eluted from the IMAC resin was comparable to that
obtained with the two-step purification (data not shown). It bears
noting that the IMAC yields for AlgL-His were at least 3-fold
greater than any previously reported purification of the enzyme
from shake flask cultures (28, 29). Importantly, kinetic analysis
(described below) showed that the IMAC-purified proteins were
indistinguishable from samples prepared by two-step chromatog-
raphy.
Solution phase enzyme kinetics. Intuition suggests that the
therapeutic potential of alginate lyase enzymes should be directly
proportional to their catalytic firepower, and therefore, the solu-
tion phase kinetics of alginate degradation were used to compare
the prospective utilities of the various enzymes (Table 1). Initial
studies were conducted with commercially available BSWA, a
standard substrate for analysis of alginate lyase activity. In com-
paring the two native enzyme constructs, A1-III exhibited a 10-
fold greater Vmax than AlgL, but the difference in Km values was
not statistically significant. With the BSWA substrate, the Vmax
andKm values for the nativeA1-III enzymewere similar to those of
theHis-tagged analog A1-III–His, as were the respective values for
AlgL and AlgL-His. Thus, appending a C-terminal hexahistidine
tag onto either of the two alginate lyases did not substantially alter
their solution phase kinetics.
BSWA is a readily available commodity product commonly
used for characterizing alginate lyase activity, but the ultimate
therapeutic target is alginate produced by the bacterium P. aerugi-
FIG 1 SDS-PAGE analysis of alginate lyase expression and purification. (A) P. aeruginosaAlgL. Lane 1, Bio-Rad Precision Plus Dual Color Standard; lane 2, AlgL
soluble cell-free extract; lane 3, AlgL-His soluble cell-free extract; lane 4, AlgL eluted from hydroxyapatite; lane 5, AlgL-His eluted from hydroxyapatite; lane 6,
AlgL following size exclusion chromatography; lane 7, AlgL-His following size exclusion chromatography. (B) Sphingomonas sp. A1-III. Samples containing the
native and His-tagged proteins were loaded as for panel A.
TABLE 1 Pseudo Michaelis-Menten kinetic parameters with BSWA and
bacterial (FRD1) alginate substrates
Enzyme Substrate
Vmax
[A235 (min · mg)
1] Km (g/ml) Vmax/Km
AlgL BSWA 26 1 70 10 0.36 0.05
AlgL-His BSWA 35 2 40 10 0.8 0.2
FRD1 127 6 840 70 0.15 0.01
Al-III BSWA 290 20 39 9 8 2
Al-III–His BSWA 337 9 100 10 3.4 0.4
FRD1 310 10 420 40 0.74 0.08
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nosa. Bacterial alginate differs from BSWA in its relative mannu-
ronic and guluronic acid content, as well as the presence of acetyl
esters on C-2 and C-3 hydroxyl groups (30). To compare the ac-
tivities of the two enzymes on a more clinically relevant substrate,
the kinetics of A1-III–His and AlgL-His were determined with
alginate purified from P. aeruginosa strain FRD1, a mucoid clini-
cal isolate (Table 1). TheVmax value for A1-III–His was essentially
unchanged compared to its value with the BSWA substrate, but
the enzyme’s Km for bacterial alginate was at least 4-fold higher.
Thus, A1-III–His exhibited strong activity toward both BSWA
and bacterial alginate, but it required substantially higher concen-
trations of the latter to achieve maximum rates of degradation.
The AlgL-His enzyme, on the other hand, was found to have a
significant increase in bothKm (20-fold) andVmax (3.6-fold)when
comparing the bacterial substrate to BSWA. The P. aeruginosa
enzyme, therefore, achieves highermaximum rates of degradation
with its native bacterial substrate, but analogous to A1-III–His, it
requires concentrated substrate solutions to do so. Despite the
increased activity of AlgL-His toward its native substrate, the A1-
III–His enzymemaintained a significant advantagewith respect to
themaximumdegradation rates of bacterial alginate (
2-fold). In
contrast, the catalytic efficiencies (Vmax/Km) of the two enzymes
were not significantly different for the therapeutically relevant
substrate.
Treatment of mucoid and nonmucoid biofilms with A1-III–
His and tobramycin. Within the hydrogel environment of bacte-
rial biofilms, onemay reasonably assume that the local concentra-
tions of alginate will be quite high. Under conditions of high
substrate concentration,Vmax, as opposed toVmax/Km, is themost
relevant kinetic parameter. We therefore elected to examine only
A1-III–His in the initial biofilm assays. While we had previously
validated the biofilm-disrupting potential of A1-III–His using lec-
tins to quantify alginate in enzyme-linked immunosorbent assay
(ELISA)-type assays (12), here, we sought to quantify bactericidal
activity within established biofilms. The alamarBlue reagent had
been validated previously as an accurate reporter of P. aeruginosa
viability in both planktonic cultures and biofilms (31). Thus, ala-
marBlue was used to monitor relative viability in the subsequent
studies.
Treatment of mucoid FRD1 biofilms with 500 g/ml of tobra-
mycin, a clinically relevant concentration (32), resulted in a 48%
reduction in cell viability compared to untreated controls (Fig.
2A). Standalone treatment with 1,000 g/ml of A1-III–His
showed a 40% reduction in alamarBlue signal, which likely re-
sulted from enzyme-mediated cellular detachment as opposed to
direct bactericidal action. In contrast, the combination of the two
treatments (500 g/ml tobramycin with 1,000 g/ml of A1-III–
His) repeatedly resulted in complete elimination of viable cell sig-
nal. Given the exceptional efficacy of the combined treatment on
FRD1 biofilms, a simple control study was designed to confirm
that the synergistic effect was a function of alginate degradation.
Specifically, the treatment study with tobramycin and A1-III–His
was repeated using the isogenic, nonmucoid P. aeruginosa strain
SMC406 (Fig. 2B). The tobramycin treatment, lowered to 100
g/ml to account for the greater sensitivity of nonmucoid strains
(7), failed to reduce viable cells in the biofilm to a statistically
significant degree. Surprisingly, the standalone A1-III–His treat-
ment reduced alamarBlue signal by 40%, the same as observed
with FRD1. Also similar to the results with FRD1, the combina-
tion treatment reduced SMC406 cell viability to background lev-
els. These results were unanticipated, as the SMC406 strain does
not produce alginate and should therefore be unaffected by alg-
inate lyase treatment.
Given the unexpected results with the nonmucoid SMC406
strain, studies were designed to more rigorously assess the role of
alginate degradation in FRD1 biofilm disruption. Based upon an
X-ray crystal structure and a hypothesized mechanism (25), an
active-site double mutant (H188A and Y242F) of A1-III–His was
constructed (here, the double mutant is referred to as A1-DM-
His). The A1-DM-His protein was expressed and purified at levels
comparable to A1-III–His, but the purified double mutant exhib-
ited no detectable activity on BSWA, even at enzyme concentra-
tions 40-fold higher than those used to characterize the active
biocatalyst (data not shown). The inactive A1-DM-His enzyme
was used to treat both mucoid FRD1 and nonmucoid SMC406
biofilms alone and in combination with tobramycin (Fig. 2). As a
single-agent treatment, A1-DM-His reduced biofilm signals by
25%,whereas in combinationwith tobramycin, it reduced biofilm
FIG 2 Analysis of cell viability in P. aeruginosa biofilms following alginate lyase treatments. (A) Mucoid FRD1 biofilms were treated for 12 h with either 500
g/ml tobramycin (Tob), 1,000g/ml alginate lyase, or a combination thereof. Subsequently, cell viability was quantified with alamarBlue, and the results were
normalized to untreated biofilms. (B)Nonmucoid SMC406 biofilmswere treated in the samemanner as for panel A, except that tobramycin concentrations were
lowered to 100 g/ml. The error bars represent standard deviations from four replicates. Statistically significant (  0.05) differences relative to untreated
biofilms are marked with asterisks.
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cell signals to background levels. The latter result was indistin-
guishable from those achieved with the wild-type enzyme and
tobramycin combination. Thus, it was concluded that A1-III–His
antibacterial synergy with tobramycin was decoupled from cata-
lytic activity.
Treatment of mucoid biofilms with proteins lacking alg-
inate-degrading activity. While the above-mentioned results
demonstrated that catalytic activity was irrelevant to biofilm dis-
persion and tobramycin synergy, they did not rule out the possi-
bility that the observed antibiofilm effects resulted from some
other molecular feature specific to the A1-III alginate lyase pro-
tein. To test this hypothesis, the FRD1 biofilm studies were re-
peated with the inactive A1-DM-His enzyme, as well as BSA as a
sham treatment (Fig. 3A). In addition to analyzing cell viability
within the treated biofilms, viable cells were also quantified in the
treatment supernatant itself. Thus, the new studies captured the
treatment effects on both adherent and detached cell populations.
BSA treatment affected neither biofilmnor planktonic alamarBlue
signal. When used in combination with tobramycin, however,
BSA essentially eradicated viable cells from both the planktonic
and biofilm states. Likewise, A1-DM-His combined with tobra-
mycin again eradicated the biofilm cells (consistent with the re-
sults shown in Fig. 2A) and left few viable cells in the planktonic
state. In aggregate, these results indicated that the observed tobra-
mycin synergy was not a function of any specific alginate lyase
property but was more likely a nonspecific phenomenon stem-
ming from biofilm exposure to proteins in general.
Amino acid treatment of mucoid biofilms. In an effort to as-
sess whether intact primary/secondary/tertiary protein structure
was required for antibiofilm synergy with tobramycin, a panel of
individual amino acid mixtures was examined next. Each treat-
ment was based on themolar concentration of the individual con-
stituent amino acids in 1,000 g/ml intact A1-III–His. Treatment
with either the full complement of constituent amino acids (A1-
III–His AA) or just the constituent arginines of A1-III–His (A1-
III–His Arg) did not affect the biofilm cell signal but did increase
the planktonic cell signal (Fig. 3B). Treatment with arginine at a
molar concentration equal to that of the sum total of all individual
constituent amino acids (arginine) yielded a 2-fold increase in the
biofilm signal and a 5-fold increase in the planktonic cell signal.
These observations suggest that the amino acids were used as a
nutrient source in the otherwise nutrient-depleted buffer, and
they are also consistent with the prior use of arginine as a growth
supplement for P. aeruginosa biofilms (33). As observed in the
earlier trials, tobramycin alone yielded only a moderate reduction
in cell viability (36% for biofilm and 26% for planktonic cells). In
combination with tobramycin, however, each of the amino acid
treatments resulted in complete knockdown of the biofilm cell
signal. The combined treatments were found to retain some level
of planktonic cell viability, but the levels were at least 55% lower
than those observed with tobramycin treatment alone. Thus,
amino acid mixtures were as good as or even better than intact
proteins with respect to bactericidal synergy toward biofilm cells.
Alginate lyase proteolytic sensitivity as a parameter in mu-
coid biofilm treatments. The above-mentioned results suggested
that the alginate lyase treatments manifested antibiotic synergy by
virtue of their consumption as a nutrient source, which would
necessitate proteolytic degradation of the enzymes. As a prelimi-
nary test of this hypothesis, mucoid biofilms were treated with an
active alginate lyase that had been conjugated to a 20-kDa poly-
FIG 3 Analysis of P. aeruginosa viability following biofilm treatments.Mucoid FRD1 biofilmswere treated for 12 hwith a panel of biologic reagents, tobramycin,
or combinations thereof. alamarBluewas thenused to quantify cell viability in the remaining adherent biofilm (black bars), aswell as in the treatment supernatant
containing detached planktonic cells (white bars). (A) A1-DM-His alginate lyase and BSA were used to assess the effects of protein treatments that lacked
alginate-degrading activity. (B) Treatments consisting of individual amino acids were used to assess whether higher-order protein structure was required for
tobramycin synergy. The treatments were composed of (i) A1-III–His AA, with each individual amino acid at the same concentration as its specific molar
contribution to 1,000 g/ml intact A1-III–His; (ii) A1-III–His Arg, with arginine at the same concentration as its specific molar contribution to 1,000 g/ml
intact A1-III–His; and (iii) arginine, with arginine at the samemolar concentration as the total of all individual amino acids in 1,000g/ml intact A1-III–His. (C)
Treatment with diverse alginate lyase enzymes was used to assess the effects of varied catalytic activity and proteolytic sensitivity. A1-III–His was repeated as a
positive control. AlgL-His was included as a reduced-activity enzyme evolved to function specifically on bacterial alginate. A53C-His-PEG is a genetically
engineered and PEGylated variant of A1-III–His that exhibits nearly identical solution phase kinetics but should have greater resistance to proteolytic degrada-
tion. The error bars represent standard deviations from six replicates. For biofilm cells, statistically significant ( 0.05) differences relative to untreated biofilm
are marked with asterisks. For planktonic cells, statistically significant (  0.05) differences relative to untreated biofilm are marked with pound signs.
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ethylene glycol chain, i.e., PEGylated. PEGylation is a well-vali-
datedmethodof reducing the proteolytic susceptibility of proteins
(34, 35), and the PEGlyated alginate lyase (A53C-His-PEG) had
been shown previously to exhibit wild-type solution phase kinet-
ics and better than wild-type biofilm disruption (12). Treatment
of mucoid biofilms with A1-III–His once again showed a de-
creased biofilm cell signal and at the same time an increased
planktonic cell signal, which is consistent with enzyme-mediated
detachment of biofilm cells (Fig. 3C). Similar to earlier results,
A1-III–His combined with tobramycin essentially eradicated bio-
film cells. Interestingly, treatment with AlgL-His alone caused an
increase in both the biofilm cell signal and the planktonic cell
signal. A combination of AlgL-His and tobramycin, however,
yielded the expected knockdown of bacterial viability. Similar to
AlgL alone, treatment with only A53C-His-PEG resulted in both
increased biofilm cell signal and planktonic cell signal. In sharp
contrast to all other combination treatments, however, A53C-
His-PEG with tobramycin was no different than tobramycin
alone. Thus, the PEGylated alginate lyase was the only biological
treatment that failed to exhibit synergy with tobramycin.
Analysis of treatments by SEM. The alamarBlue assays of cell
viability consistently pointed to a catalysis-independent mode of
action for the alginate lyases, but to corroborate these results, the
biofilm treatment studies were repeated and SEM was used to
visualize treated biofilms in a direct fashion. Importantly, pre-
SEM alamarBlue testing of these biofilms gave results matching
those from the initial studies described above (data not shown).
Representative images at8,000 magnification (Fig. 4) highlight
the differential effects of various treatments with respect to bio-
film architecture, total biomass, and vitality of adherent cells.
Blank buffer treatment of biofilms resulted in bacterial cells em-
bedded within robust and copious extracellular matrix. In the
absence of tobramycin, treatment with A1-III–His or A1-DM-His
caused the nearly complete removal of extracellular matrix. As
single agents, A53C-His-PEG and BSA also appeared to remove
the majority of biofilm matrix, but each appeared to subtly in-
crease the number of attached cells compared to biofilms treated
with the wild-type A1-III–His enzyme. Importantly, the qualita-
tive SEManalysis ofmatrix removal byA1-III–His andA53C-His-
PEG showed good agreement with prior quantitative analysis
based on binding of an alginate-sensitive lectin (12). In contrast to
the intact proteins, treatment with the constituent amino acids
resulted in only partial removal of the biofilm matrix and a dra-
matic increase in the density of attached cells. Following treatment
with biological agents, the bacteria generally appeared to have
intact structure and regular shape, although some deviations from
normal morphology were seen with the A53-His-PEG standalone
treatment (Fig. 4D).
SEM analysis of biofilms treated with combinations of tobra-
mycin and biologics again showed that the biological agents con-
tributed to a reduction in extracellular matrix. Compared to the
results from biological agents alone, the only differences were that
the amino acid treatment with tobramycin left no identifiablema-
trix (compare Fig. 4E and 5E) while A53C-His-PEG with tobra-
mycin yielded more matrix than the enzyme alone (compare Fig.
4D and 5D). More striking was the effect of tobramycin treat-
ments on cellular integrity. As a single agent, the antibiotic yielded
a subpopulation of adherent cells with atypical membrane mor-
phology (Fig. 5A). The combination of tobramycin with A53C-
His-PEG yielded largely similar results (Fig. 5D). In contrast, few
if any intact adherent cells could be identified from biofilms
treated with combinations of tobramycin and A1-III–His, A1-
DM-His, BSA, or A1-III–His AA; only ghost cells were observed
(Fig. 5B, C, E, and F).
Overall, SEM imaging correlated well with the results of
alamarBlue viability analysis. One apparent discrepancy was the
A53C-His-PEG treatment versus the PBS control. The quantita-
tive alamarBlue studies showed that biofilms treated with the
PEGylated enzyme exhibited almost 2-fold-higher signals than
those treated with PBS. The SEM images, on the other hand, sug-
gest a dramatic reduction in total biomass upon treatment with
A53C-His-PEG. It is important to note that the alamarBlue re-
agent measures cellular metabolic activity, and it is therefore in-
sensitive to biofilm matrix components, which constitute a sub-
FIG 4 Representative SEM images of FRD1 biofilms treated with buffer only (A), A1-III–His (B), A1-DM-His (C), A53C-His-PEG (D), A1-III–His AA (E), or
BSA (F). The distinct architecture of biofilm matrix versus simple adherent cells is clear in panel A compared to panel B, C, D, or F.
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stantial fraction of the biomass seen in PBS-treated biofilms (Fig.
4A). Moreover, as noted above, some fraction of cells fromA53C-
His-PEG-treated biofilms exhibited anomalous morphology (Fig.
4D). This atypical morphology might correlate with altered cellu-
lar metabolic activity, which could in turn impact the alamarBlue
assay. Together, these observations might explain the apparent
discrepancy between alamarBlue and SEM analyses of A53C-His-
PEG- versus PBS-treated biofilms.
DISCUSSION
P. aeruginosa’s persistence in the CF airway can, to a large extent,
be attributed to the bacterium’s biofilm mode of growth (36).
Additionally, P. aeruginosa’s transition to a mucoid phenotype in
the majority of CF patients (1) leads to alginate-rich biofilms and
enhanced antibiotic resistance (7). Therefore, disruption of the
mucoid biofilm architecture with alginate lyases has long been
considered a promising approach for enhancing antibiotic effi-
cacy (16), and recent studies support this hypothesis (17, 19). In
contrast, at least one report showed that exogenously added Azo-
tobacter vinelandii alginate lyase failed to remove mucoid P.
aeruginosa biofilms despite the enzyme’s confirmed activity to-
ward the alginate substrate (37). One explanation for such an out-
come is that the alginate biopolymer has a negligible contribution
tomucoid biofilmadhesion (38). Regardless, the apparent discon-
nect between reports of alginate lyase antibiotic synergy versus
enzyme-mediated biofilm disruptionmotivated the design of sys-
tematic studies to more fully assess the antibacterial potential of
these biocatalysts.
Alginate lyase A1-III–His was selected over AlgL-His for the
initial biofilm cell viability assays as a result of the enzyme’s
superior alginate degradation kinetics. SEM analysis showed
that A1-III–His drastically reduced extracellular matrix com-
pared to untreated and tobramycin-treated biofilms. Addition-
ally, cotreatment of biofilms with A1-III–His and tobramycin
demonstrated a vast improvement in cell killing compared to no
treatment or tobramycin-only treatment. These results are consis-
tent with a long series of prior reports demonstrating cooperativ-
ity between alginate lyases and antibiotics (14, 16–18). Surpris-
ingly, equivalent results were obtained in controlled studies with
an isogenic nonmucoid strain that does not produce alginate ex-
opolysaccharide. Although not peer reviewed, a recent report
from theUniversity of BritishColumbia found similar results with
the nonmucoid P. aeruginosa strain PAO1 (39), which also fails to
produce alginate under typical growth conditions (40). These ob-
servations suggested that alginate lyase catalytic activity was not a
requisite factor for biofilm disruption or synergy with the antibi-
otic tobramycin. To test this hypothesis, we repeated our biofilm
cell viability assays with the genetically inactivated alginate lyase
A1-DM-His, as well as BSA sham treatments. Both catalytically
inactive proteins yielded SEM evidence of biofilm dispersion and
exhibited enhanced killing of biofilm cells when used in combina-
tion with tobramycin. Thus, biofilm dispersal and increased anti-
biotic efficacy appear to be nonspecific effects manifested by pro-
teins in general. While early reports showed that heat-treated
alginate lyase improved macrophage uptake of P. aeruginosa (15),
the results reported here represent the first direct evidence that
alginate lyase catalytic activity is superfluous to biofilm disruption
and antibiotic synergy.
An alternative explanation for the antibiofilm effects of alg-
inate lyases could be related to enzyme-mediated changes in cell
physiology. Indeed, there is evidence that the growth behavior of
P. aeruginosa and other biofilm-associated cells is a greater con-
tributor to antibiotic resistance than any physical barrier the bio-
film matrix might provide (41, 42). Nutrient limitation within
biofilm communities leads to a general reduction in cellular me-
tabolism (43), as well as specific response mechanisms that in-
crease antibiotic tolerance (44). Another key piece of the puzzle is
that P. aeruginosa biofilms can be dispersed by sudden increases in
carbon source availability (45), and it has been shown that this
effect depends upon protein synthesis (46). Additionally, arginine
treatment is thought to upregulate the metabolism of P. aerugi-
nosa in anaerobic biofilms, and it thereby increases antibiotic ef-
FIG 5 SEM images of FRD1 biofilms treated with tobramycin (A), tobramycin and A1-III–His (B), tobramycin and A1-DM-His (C), tobramycin and
A53C-His-PEG (D), tobramycin and A1-III–His AA (E), or tobramycin and BSA (F).
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ficacy by 10- to 100-fold (47). Thus, even simple nutrients have
the potential to profoundly influence adherent cell behavior
and/or modulate antibiotic efficacy toward biofilms.
These insights motivated a hypothesis that, as opposed to ac-
tively degrading biofilm matrix, alginate lyases were acting as a
nutrient source, modulating cellular metabolism and thus induc-
ing cellular detachment and enhancing tobramycin efficacy. To
test this hypothesis, biofilms were treated with the individual
amino acid components of A1-III–His alginate lyase.With respect
to enhancing tobramycin efficacy, the amino acid cotreatments
matched the effectiveness of the intact enzyme. In the absence of
tobramycin, however, SEM imaging showed the amino acid treat-
ments failed to completely remove biofilm matrix surrounding
the adherent cells. This contrasted with the intact A1-III–His, A1-
DM-His, or BSA treatment, each of which individually resulted in
complete erosion of the biofilm matrix. A potential explanation
for the observed differences in the dispersive potential of intact
proteins versus constituent amino acids relates to bioavailability.
During infection, bacteria encounter nutrient-depleted environ-
ments and secrete proteases that can, through various mecha-
nisms, facilitate degradation of host proteins for use as a nutrient
source (48, 49). At the same time, several secreted pseudomonal
proteases have been implicated in the degradation of structural
proteins or adhesins that contribute to biofilm formation (50, 51).
Together, these facts suggest a nonintuitive mechanism for the
antibiofilm effects of alginate lyases: (i) biofilm bacteria sense the
intact protein treatments and in response secrete proteases, (ii)
subsequent assimilation of the freed amino acids upregulates cel-
lular metabolism and renders the bacteria more susceptible to
killing by tobramycin, and (iii) the secreted proteases destabilize
key components of the biofilm matrix and initiate biofilm disso-
lution. Although this mechanism is speculative in nature, the lit-
erature supports each postulate independently, and their pro-
posed connectivity is consistent with the observations reported
here.
The above hypothesis was tested in a preliminary fashion by
treating mucoid biofilms with the A53C-His-PEG alginate lyase,
whose pendent 20-kDa PEG chain should at least partly shield the
protein from proteases. Consistent with prior reports of the en-
zyme’s ability to disrupt mucoid biofilms (12), SEM imaging re-
vealed that A53C-His-PEG itself caused nearly complete dissolu-
tion of the biofilm matrix. The above-described mechanism
would predict this outcome, if indeed the bacteria sensed the en-
zyme and subsequently secreted proteases. In contrast to all other
intact protein treatments, however, a combination of A53C-His-
PEG with tobramycin was no more effective at killing than treat-
ment with tobramycin alone. Again, this is consistent with the
proposed mechanism, if tobramycin synergy is ultimately depen-
dent on the presence of individual amino acids, which are less
readily liberated from the PEGylated enzyme. As a corollary, di-
rect treatment of biofilms with constituent amino acids manifests
a less pronounced degradation of biofilm matrix but fully repli-
cates the intact proteins’ synergy with tobramycin. Regardless of
the mechanistic details, the studies reported here demonstrate
that protein treatments nonspecifically promote P. aeruginosa
biofilm dispersal, and they may enhance tobramycin efficacy
through the action of their constituent amino acids.
Taken together, the above results reveal that complete biofilm
dispersal is neither sufficient nor required for tobramycin synergy
with biological cotreatments. Importantly, the results disclosed
here do not contradict prior reports of therapeutically relevant
activity among alginate lyases. Indeed, they reinforce the widely
published conclusions that this class of enzymes manifests bio-
film-dispersive properties and synergy with antibiotics, yet the
current studies are the first to probe the mechanism underlying
these effects. In the biofilm model used here, alginate lyase cata-
lytic activity is irrelevant to biofilm dispersion and tobramycin
synergy. In fact, equivalent disruption of the biofilm matrix is
achieved with the commodity protein BSA, and equivalent tobra-
mycin synergy is achieved with either BSA or simple amino acids.
While further work is required to extend the current studies to
more clinically relevant models, it is clear that the long history of
alginate lyase enzyme therapies should be reexaminedwith amore
critical eye. In particular, the motivating assumption that enzy-
matic degradation of alginate would drive therapeutic effects may
well be unfounded.
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